<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741646</url>
  </required_header>
  <id_info>
    <org_study_id>1U01DK122013-01</org_study_id>
    <nct_id>NCT04741646</nct_id>
  </id_info>
  <brief_title>Ferric Citrate and Chronic Kidney Disease in Children</brief_title>
  <acronym>FIT4KID</acronym>
  <official_title>Phosphate Binder Therapy and Chronic Kidney Disease in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the&#xD;
      effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23,&#xD;
      primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-17 years of&#xD;
      either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum&#xD;
      phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC&#xD;
      placebo. Participants will be recruited from 12 core clinical sites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will conduct a double-blind, randomized, placebo-controlled trial to assess the effects of&#xD;
      therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint)&#xD;
      aged 6-17 years of either sex with chronic kidney disease (CKD) stages 3-4 and&#xD;
      age-appropriate normal serum phosphate levels. Participants will be randomized to one of the&#xD;
      two groups: 1) FC or 2) FC placebo. Participants will be recruited from 12 core clinical&#xD;
      sites.&#xD;
&#xD;
      Schedule of Intervention: During the 12-month trial, participants will be given a daily fixed&#xD;
      weight-based dose of FC.&#xD;
&#xD;
      Schedule for data collection/analyses to be performed:&#xD;
&#xD;
      Blood for primary outcome assessments will be collected at screening, baseline and at months&#xD;
      1, 2, 3, 6, 9, 12. Blood for safety assessments will be collected at the same intervals.&#xD;
&#xD;
      The primary analyses for this 2-arm trial will evaluate changes from baseline in iFGF23&#xD;
      levels over 12 months between the treatment and the placebo arms. The analysis will use a&#xD;
      linear mixed-effects model, with random participant effects accounting for repeated&#xD;
      measurements, random site effects accounting for clustering of participants into study sites,&#xD;
      and a fixed treatment effect, which interacts with a time indicator (Months 3-12 vs. Months&#xD;
      1-3).&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
        -  To assess the effects of therapy with FC on changes in iFGF23 levels&#xD;
&#xD;
        -  To determine safety and tolerability of FC.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      • To assess the effects of FC on anemia and indices of mineral and bone metabolism.&#xD;
&#xD;
      Primary Endpoint:&#xD;
&#xD;
      • Change in iFGF23 level&#xD;
&#xD;
      Safety and Tolerability Endpoints:&#xD;
&#xD;
      • Ability to safely tolerate FC&#xD;
&#xD;
      Secondary Endpoints:&#xD;
&#xD;
        -  Change in anemia&#xD;
&#xD;
        -  Change in the indices of mineral and bone metabolism&#xD;
&#xD;
      This is a Phase 2 study with participation from 12 sites that will take 36 months to complete&#xD;
      enrollment and a total of 48 months to complete data collection with each participant being&#xD;
      part of the study for 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iFGF23 levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Change in iFGF23 levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Ferric Citrate</measure>
    <time_frame>12 months</time_frame>
    <description>Safety of FC will be compared to Placebo through measures of Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of Ferric Citrate</measure>
    <time_frame>12 months</time_frame>
    <description>Tolerability of FC will be compared to Placebo through measures of Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on Hemoglobin</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in Hemoglobin will be compared between FC and Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on TSAT</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in TSAT will be compared between FC and Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Ferritin</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in Ferritin will be compared between FC and Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on PTH</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in PTH will be compared between FC and Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on 1,25 D</measure>
    <time_frame>12 months</time_frame>
    <description>Decrease in 1,25 D will be compared between FC and Placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the 12-month trial, participants will be given a fixed weight-based dose of Ferric Citrate (FC). The full medication dose will be 3g/day for participants weighing &lt;31 kg, 5g/day for those weighing &gt;31 - &lt;51 kg, and 6g/day for participants &gt;51 kg. These doses will be divided into three doses to be taken with meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the 12-month trial, participants will be given a fixed weight-based dose of Placebo. The full medication dose will be 3g/day for participants weighing &lt;31 kg, 5g/day for those weighing &gt;31 - &lt;51 kg, and 6g/day for participants &gt;51 kg. These doses will be divided into three doses to be taken with meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Citrate</intervention_name>
    <description>Auryxia® 210 mg ferric iron tablets equivalent to 1 g of FC and matching placebo will be supplied as 200 tablets in 400cc high-density polyethylene bottles.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match Ferric Citrate tablets</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 6 to 17 years (inclusive);&#xD;
&#xD;
          2. Estimated GFR of 15-59 ml/min per 1.73 m2 by modified CKiD formula;56&#xD;
&#xD;
          3. Serum phosphate within age appropriate normal levels;&#xD;
&#xD;
          4. Serum ferritin &lt;500 ng/ml and TSAT &lt;50%;&#xD;
&#xD;
          5. For those patients treated with growth hormone, calcitriol, nutritional vitamin D,&#xD;
             iron, and/or ESAs such treatments must have stable dosing for at least 2 weeks prior&#xD;
             to screening;&#xD;
&#xD;
          6. Able to swallow tablets;&#xD;
&#xD;
          7. Able to eat at least two meals a day;&#xD;
&#xD;
          8. In the opinion of the investigator, willing and able to follow the study treatment&#xD;
             regimen and comply with the site investigator's recommendations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Perform physical exam and obtain vitals.&#xD;
&#xD;
          2. Check urine pregnancy test in menstruating female participants and administer&#xD;
             corresponding questionnaire.&#xD;
&#xD;
          3. Administer GI Symptom questionnaire.&#xD;
&#xD;
          4. Ascertain AEs.&#xD;
&#xD;
          5. Obtain information on concomitant medications.&#xD;
&#xD;
          6. Process 24-hour urine sample for 24 hour urine creatinine and phosphate.&#xD;
&#xD;
          7. Measure run-in adherence using eCAP system and pill count.&#xD;
&#xD;
          8. Administer the Medical Adherence Measure tool.&#xD;
&#xD;
          9. Reinforce adherence.&#xD;
&#xD;
         10. Prepare one month's supply of drug and enter them into eCAP system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isidro B Salusky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JENNY BROOK, MS</last_name>
    <phone>310-7943144</phone>
    <email>jbrook@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Gales, RN</last_name>
    <email>bgales@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Barbara Gales, RN</last_name>
      <phone>310-206-0799</phone>
      <email>bgales@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Isidro Salusky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Schrader</last_name>
      <phone>415-476-9657</phone>
      <email>daniel.schrader@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Portale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jorge Ramirez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anjali Khanna</last_name>
      <phone>470-867-7765</phone>
      <email>anjali.khanna@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mone Anzai</last_name>
      <phone>404-712-9923</phone>
      <email>mone.anzai@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Laurence Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital, Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephen Morrison</last_name>
      <phone>816-302-3573</phone>
      <email>ssmorrison@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley Warady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Patricia Flynn</last_name>
      <phone>718-655-1120</phone>
      <email>pflynn@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Frederick Kaskel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bliss Magella, PhD</last_name>
      <phone>513-636-7832</phone>
      <email>bliss.magella@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Mark Mitsnefes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nia Nichols</last_name>
      <phone>215-427-4294</phone>
      <email>nia.nichols@towerhealth.org</email>
    </contact>
    <investigator>
      <last_name>Joshua Zaritsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center, Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Melaku Lemma</last_name>
      <phone>214-456-8577</phone>
      <email>melaku.lemma@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Raymond Quigley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Saima Deen</last_name>
      <phone>832-824-7783</phone>
      <email>sxdeen@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Poyyapakkam R Srivanthos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Mike Guron</last_name>
      <phone>604-875-2000</phone>
      <phone_ext>7255</phone_ext>
      <email>mike.guron@bcchr.ca</email>
    </contact>
    <contact_backup>
      <last_name>Julie Matheson</last_name>
      <phone>604-875-2000</phone>
      <phone_ext>7558</phone_ext>
      <email>jmatheson@bcchr.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Tom Blydt-Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Isidro Salusky, MD</investigator_full_name>
    <investigator_title>Distinguished Professor of Pediatrics at the David Geffen School of Medicine at UCLA, Chief of Pediatric Nephrology and Director of the Pediatric Dialysis Program</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>CKD</keyword>
  <keyword>Phosphate Binder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

